Inhibrx, Inc. (INBX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Inhibrx, Inc. (INBX) is up 18.1% since the beginning of the year. At $93 per share, INBX is trading 39.9% below its 52-week high of $155.

Inhibrx, Inc. (INBX) has returned 18.10% so far this year and 524.92% over the past 12 months.

Based on dividend-adjusted daily data since May 29, 2024, INBX's average daily return is +0.54%, while the average monthly return is +11.67%. At this rate, an investment would double in approximately 0.5 years.

Historically, 58% of months were positive and 42% were negative. The best month was Oct 2025 with a return of +142.5%, while the worst month was May 2026 at -19.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, INBX closed higher 52% of trading days. The best single day was Oct 24, 2025 with a return of +102.0%, while the worst single day was Oct 22, 2025 at -16.0%.

Inhibrx, Inc. has an annualized alpha of 201.21%, beta of 1.39, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since May 29, 2024.

• This stock captured 773.92% of S&P 500 Index gains but only 72.54% of its losses - a favorable profile for investors.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INBX ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Inhibrx, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Inhibrx, Inc. was 39.84%, occurring on May 14, 2025. Recovery took 35 trading sessions.

The current Inhibrx, Inc. drawdown is 34.22%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Inhibrx, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Inhibrx, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.